State Street Corp Has $39.53 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

State Street Corp increased its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 7.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,750,643 shares of the company’s stock after purchasing an additional 116,534 shares during the quarter. State Street Corp owned approximately 1.45% of 10x Genomics worth $39,530,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of 10x Genomics by 451.8% in the third quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after buying an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in shares of 10x Genomics during the 3rd quarter valued at $35,000. Allspring Global Investments Holdings LLC grew its position in shares of 10x Genomics by 134.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company’s stock valued at $32,000 after purchasing an additional 939 shares in the last quarter. Blue Trust Inc. lifted its position in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Sound Income Strategies LLC purchased a new position in shares of 10x Genomics in the 3rd quarter worth about $46,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ:TXG opened at $14.04 on Friday. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -9.18 and a beta of 1.84. 10x Genomics, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $57.78. The firm has a fifty day moving average price of $15.29 and a 200 day moving average price of $18.71.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm had revenue of $151.65 million during the quarter, compared to the consensus estimate of $158.84 million. During the same period in the prior year, the company earned ($0.51) EPS. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, research analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TXG shares. JPMorgan Chase & Co. decreased their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. Canaccord Genuity Group cut their price target on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, October 10th. Barclays decreased their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. Finally, UBS Group lowered their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.14.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.